Novel Antigens and Clinical Updates in Membranous Nephropathy.
| Autor: | Avasare R; Division of Nephrology and Hypertension, Oregon Health & Science University, Portland, Oregon, USA; email: avasare@ohsu.edu., Andeen N; Department of Pathology, Oregon Health & Science University, Portland, Oregon, USA; email: andeen@ohsu.edu., Beck L; Section of Nephrology, Department of Medicine, Boston Medical Center, Boston, Massachusetts, USA.; Section of Nephrology, Department of Medicine, Boston University Chobanian & Avedisian School of Medicine, Boston, Massachusetts, USA. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Annual review of medicine [Annu Rev Med] 2024 Jan 29; Vol. 75, pp. 219-332. Date of Electronic Publication: 2023 Aug 08. |
| DOI: | 10.1146/annurev-med-050522-034537 |
| Abstrakt: | Membranous nephropathy (MN), an autoimmune kidney disease and leading cause of nephrotic syndrome, leads to kidney failure in up to one-third of affected individuals. Most MN cases are due to an autoimmune reaction against the phospholipase A2 receptor (PLA2R) located on kidney podocytes. Serum PLA2R antibody quantification is now part of routine clinical practice because antibody titers correlate with disease activity and treatment response. Recent advances in target antigen detection have led to the discovery of more than 20 other podocyte antigens, yet the clinical impact of additional antigen detection remains unknown and is under active investigation. Here we review recent findings and hypothesize how current research will inform future care of patients with MN. |
| Databáze: | MEDLINE |
| Externí odkaz: |
|